Oncology

News

AstraZeneca buys cell therapy biotech for up to $1bn

AstraZeneca plans to acquire Belgian in vivo cell therapy biotech EsoBiotec and has signed a pair of licensing deals with drug delivery firm Alteogen.

News

Taiho snaps up ADC partner Araris for up to $1.14bn

Taiho has reached a deal to buy Swiss biotech Araris, around 18 months after they started collaborating on antibody-drug conjugates for cancer.

News

AbbVie builds the case for ovarian cancer drug Elahere

AbbVie hopes for another lift to its fast-growing ovarian cancer drug Elahere with new survival data.

News

Sutro puts lead ADC on hold, cuts staff and changes CEO

Sutro has shelved its lead drug for ovarian cancer and turned its attention to three preclinical candidates in a major shake-up of its business.

News

Kelun-Biotech first to bag TROP2 approval in lung cancer

Kelun-Biotech wins first global regulatory approval - in China - for a TROP2-directed antibody-drug conjugate (ADC) in lung cancer.

News

Pfizer's new drug data in breast cancer draws muted response

Pfizer and Arvinas' much-anticipated oral SERD vepdegestrant for breast cancer missed a key endpoint in its first phase 3 readout.

AstraZeneca buys cell therapy biotech for up to $1bn

Taiho snaps up ADC partner Araris for up to $1.14bn

AbbVie builds the case for ovarian cancer drug Elahere

Sutro puts lead ADC on hold, cuts staff and changes CEO

Kelun-Biotech first to bag TROP2 approval in lung cancer

Pfizer's new drug data in breast cancer draws muted response

Delivering the right behavioural ingredients for the moment,...

How to meet your physicians where they are online

Oncology

Editor's Picks